Login/SignUp

National Biopharma Mission

Grand Challenges India (GCI)

Make in India

the 3i portal
Investment for Industry Innovation & Research
  • About
    • About Us
    • Our Board
    • Code of Conduct
    • Code of Conduct (Hindi Version)
  • Programmes
    • IDEATION/VERY EARLY STAGE
    •     - SITARE
    •     - E-Yuva
    • IDEATION TO EARLY STAGE
    •     - BIG
    • IDEATION TO LATE STAGE
    •     - SBIRI
    •     - BIPP
    • TRANSLATION RESEARCH
    •     - PACE
    • SOCIAL INNOVATION
    •     - SIIP
    •     - SPARSH
    • NATIONAL BIOPHARMA MISSION
    • EQUITY FUNDING
    •     - SEED FUND
    •     - ACE FUND
    • INCUBATION
    •     - BioNEST
    • STRATEGIC RESEARCH FUNDING
    •     - BANANA FORTIFICATION
  • Partnerships
    • CEFIPRA – BPI France
    • DBT-BMGF-BIRAC
    • Early Translation Accelarator (ETA)
    • Grand Challenges India(GCI)
    • Industry Innovation Programme on Medical Electronics(IIPME)
    • LEHS (WISH)
    • NESTA
    • RAPID USAID-TB Diagnostics Programme
    • TEKES
    • TIE
    • TISS
    • UKTI (UK Trade & Investment)
    • Wellcome Trust
    • BIRAC REGIONAL CENTERS
    •     - BRIC
    •     - BREC
  • Mentorship & Capacity Building
    • Ignite
    • Workshops
  • IP & TT
    • IP & Technology Management Cell
    • Banana Biofortification
  • Call for Proposal
  • Publications
  • Contact Us
  • Technology Portal
Oraxion Therapeutics, a spin-off from BIRAC supported Aten Porus Lifesciences has entered into an "Option to License" agreement for US $125 Million with a US-based biopharma company to licence its drug ORX-301 for the treatment of rare diseases

https://www.biovoicenews.com/indian-startup-develops-drug-for-key-orphan-diseases-partners-us-firm/

http://www.prweb.com/releases/2018/02/prweb15153457.htm

http://www.businessworld.in/article/Oraxion-Executes-Exclusive-Option-to-License-ORX-301/05-02-2018-139541/

 

  • RTI
  • Compliance
  • Annual Reports
  • Tenders
  • Vacancy
  • BIRAC News
  • Loan Non re-payment
  • What's New
Best Viewed In Mozilla Firefox, Chrome -- Copyright@2016 all rights reserved
Best Viewed In Mozilla Firefox, Chrome -- Copyright@2016 all rights reserved